Rational and trial design of FASCINATE-N: a prospective, randomized, precision-based umbrella trial

2024-1-1

Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bear

2024-1-1

Dysregulation of base excision repair factors associated with low tumor immunogenicity in head and neck cancer: implication for immunotherapy

2024-1-1

Combination approach for <i>CDC73</i>-related parathyroid carcinoma in an adolescent female patient: a case report and literature review

2024-1-1

Efficiency of bladder-sparing strategies for bladder cancer: an umbrella review

2024-1-1

Bone metastasis in non-small-cell lung cancer: genomic characterization and exploration of potential targets

2024-1-1

Prognosis of patients with residual pathological disease after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy and surgery for esophageal squamous cell carcinoma: a retrospective cohort study

2024-1-1

Diagnosis and treatment of bacterial peritonitis in patients with gastrointestinal cancer: an observational multicenter study

2024-1-1

Real-world analysis of afatinib as a first-line treatment for patients with advanced stage non-small-cell lung cancer with uncommon EGFR mutations: a multicenter study in Vietnam

2024-1-1

Delays in diagnosis and surgery of sarcoma patients during the COVID-19 outbreak in Spain

2024-1-1

Current evidence of PD-1 and PD-L1 immune checkpoint inhibitors for esophageal cancer: an updated meta-analysis and synthesis of ongoing clinical trials

2024-1-1

Assessment of the impact of residual tumors at different sites post-neoadjuvant chemotherapy on prognosis in breast cancer patients and development of a disease-free survival prediction model

2024-1-1

Early evaluation of the effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer

2024-1-1

Pan-Canadian consensus recommendations for GIST management in high- and low-throughput centres across Canada

2024-1-1

The role of aberrant DNA methylation in cancer initiation and clinical impacts

2024-1-1

Trabectedin and low-dose radiation therapy in patients with advanced leiomyosarcoma

2024-1-1

Plasma ddPCR for the detection of <i>MET</i> amplification in advanced NSCLC patients: a comparative real-world study

2024-1-1

Perioperative and palliative systemic treatments for biliary tract cancer

2024-1-1

Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC

2024-1-1

Development and validation of a nomogram for Siewert II esophagogastric junction adenocarcinoma: a retrospective analysis

2024-1-1

A remnant never forgotten: the utility of circulating tumor DNA in treatment guidance of urachal cancer

2024-1-1

HR-positive/HER2-negative breast cancer arising in patients with or without <i>BRCA2</i> mutation: different biological phenotype and similar prognosis

2024-1-1

Improving olaparib exposure to optimize adverse effects management

2024-1-1

Role of immunotherapy in pulmonary sarcomatoid carcinoma: review of current approaches and related biomarkers

2024-1-1

Poor efficacy of immune checkpoint inhibitor treatment in advanced thymic carcinoma patients with liver metastases

2024-1-1

Circulating tumor DNA in patients with locally advanced rectal cancer treated with multimodal treatment

2024-1-1

Resected <i>EGFR</i>-mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study)

2024-1-1

Corrigendum to “Precision medicine in colorectal cancer: the molecular profile alters treatment strategies”

2024-1-1

Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancer

2024-1-1

A pooled analysis of clinical outcome in driver-gene negative non-small cell lung cancer patients with MET overexpression treated with gumarontinib

2024-1-1

Genetic landscape of homologous recombination repair and practical outcomes of PARPi therapy in ovarian cancer management

2024-1-1

Short-term outcomes of combined therapy with sirolimus and interferon-alpha 2b for advanced hepatic epithelioid hemangioendothelioma

2024-1-1

Techniques and status of hepatic arterial infusion chemotherapy for primary hepatobiliary cancers

2024-1-1

Prolonged progression-free survival achieved by gemcitabine, cisplatin, and albumin-bound paclitaxel for the treatment of advanced biliary tract cancers

2024-1-1

Distinct clinical characteristics in stage III rectal cancer among different age groups and treatment outcomes after neoadjuvant chemoradiotherapy

2024-1-1

Reactive cutaneous capillary endothelial proliferation following camrelizumab monotherapy or combination therapy for multi-cancers: a large-scale pooled analysis of 10 studies in China

2024-1-1

Assessment of efficacy and safety of MET tyrosine kinase inhibitors in non-small-cell lung cancer patients with MET alterations

2024-1-1

Immune checkpoint inhibitors or anti-claudin 18.2 antibodies? A network meta-analysis for the optimized first-line therapy of HER2-negative gastric cancer

2024-1-1

Prognostic value of lymph node-to-primary tumor ratio of PET standardized uptake value for nasopharyngeal carcinoma: a recursive partitioning risk stratification analysis

2024-1-1

Exceptional synergistic response of PARP inhibitor and immune checkpoint inhibitor in esophageal adenocarcinoma with a germline BRCA2 mutation: a case report

2024-1-1

The impact of the HER2-low status on conditional survival in patients with breast cancer

2024-1-1

A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15)

2024-1-1

PARP inhibitors in non-ovarian gynecologic cancers

2024-1-1

Treatment options for HER2-expressing colorectal cancer: updates and recent approvals

2024-1-1

Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer

2024-1-1

A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study)

2024-1-1

Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry

2024-1-1

Phosphaturic mesenchymal tumor with <i>de novo</i> liver metastases: a case report and literature review

2024-1-1

Challenges and opportunities in the immunotherapy era: balancing expectations with hope in small-cell lung cancer

2024-1-1

Efficacy of ferric carboxymaltose or darbepoetin alfa for chemotherapy-induced anemia in patients with esophagogastric or pancreaticobiliary cancer: a retrospective comparative study

2024-1-1